Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note released on Thursday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Down 2.7 %

Eagle Pharmaceuticals stock opened at $3.95 on Thursday. The stock has a market cap of $51.30 million, a PE ratio of 3.35 and a beta of 0.53. Eagle Pharmaceuticals has a 12-month low of $3.21 and a 12-month high of $15.91. The business’s 50-day moving average price is $4.50 and its two-hundred day moving average price is $4.66.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Eagle Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after purchasing an additional 2,630 shares during the period. Headlands Technologies LLC grew its stake in shares of Eagle Pharmaceuticals by 75.7% in the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 2,861 shares during the period. Mackenzie Financial Corp bought a new stake in Eagle Pharmaceuticals in the 2nd quarter valued at about $60,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eagle Pharmaceuticals in the 2nd quarter valued at about $65,000. Finally, Fidelis Capital Partners LLC acquired a new position in Eagle Pharmaceuticals during the 2nd quarter worth approximately $71,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.